Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study

PURPOSE: This phase Ib study defined the safety, MTD, and recommended phase II dose (RP2D) of regorafenib combined with vincristine and irinotecan (VI). Secondary objectives were evaluation of antitumor activity and pharmacokinetics (PK) of regorafenib and irinotecan. PATIENTS AND METHODS: Patients...

Full description

Bibliographic Details
Main Authors: Casanova, Michela, Bautista, Francisco, Campbell-Hewson, Quentin, Makin, Guy, Marshall, Lynley V., Verschuur, Arnauld C., Cañete Nieto, Adela, Corradini, Nadège, Ploeger, Bart A., Brennan, Barbara J., Mueller, Udo, Zebger-Gong, Hong, Chung, John W., Geoerger, Birgit
Format: Online Article Text
Language:English
Published: American Association for Cancer Research 2023
Subjects:
Clinical Trials: Targeted Therapy
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618645/
https://www.ncbi.nlm.nih.gov/pubmed/37606641
http://dx.doi.org/10.1158/1078-0432.CCR-23-0257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618645/
https://www.ncbi.nlm.nih.gov/pubmed/37606641
http://dx.doi.org/10.1158/1078-0432.CCR-23-0257

Similar Items